 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a Bearish indicator signaling AMRX's price could decline from here. Traders may explore shorting the stock or put options...

Amneal Pharmaceuticals (AMRX, $4.24) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 28, 2023

Over the last three days, A.I.dvisor has detected that AMRX's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Amneal Pharmaceuticals (AMRX, $4.29) Aroon Indicator entered an Uptrend on November 27, 2023.

Amneal Pharmaceuticals (AMRX, $4.52) Aroon Indicator entered an Uptrend on November 24, 2023.

Amneal Pharmaceuticals (AMRX, $4.45) Aroon Indicator entered an Uptrend on November 22, 2023.

Amneal Pharmaceuticals (AMRX, $4.47) Aroon Indicator entered an Uptrend on November 21, 2023.

This is a signal that AMRX's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Amneal Pharmaceuticals (AMRX, $4.47) Stochastic Oscillator left the overbought zone on November 21, 2023

Amneal Pharmaceuticals (AMRX, $4.49) Aroon Indicator entered an Uptrend on November 20, 2023.

Amneal Pharmaceuticals (AMRX, $4.57) Stochastic Oscillator left the overbought zone on November 14, 2023

This price move could be a signal that AMRX may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Amneal Pharmaceuticals (AMRX, $4.57) price may drop as it broke higher Bollinger Band on Nov 14, 2023

Amneal Pharmaceuticals Non-GAAP EPS of $0.19 beats by $0.06, revenue of $620M beats by $15.47M...

Amneal Pharmaceuticals Non-GAAP EPS of $0.19 beats by $0.06, revenue of $620M beats by $15.47M

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including complex generics and specialty-branded pharmaceuticals. The company operates through three reportable segments: Generics, Specialty, and AvKARE. The Generics segment includes a retail and institutional portfolio of approximately 260 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment is engaged in the development, promotion, sale, and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease, and endocrine disorders. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Watchers	3,986
52-Wk Low	$1.24
52-Wk High	$4.74

Market Cap	$1.31B
Volume (M)	800,135.00
52-Wk High	$4.74
52-Wk Low	$1.24

Period	Estimated	Reported	Surprise	Result
Q3'23	$0.11	$0.19	69.64%	BEAT
Q2'23	$0.10	$0.19	91.92%	BEAT
Q1'23	$0.10	$0.12	25.00%	BEAT
Q4'22	$0.21	$0.23	10.55%	BEAT
Q3'22	$0.18	$0.14	-20.84%	MISSED

AMRX Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

About

Feed

News

Sentiment

Earnings

Fundamentals